BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7998778)

  • 1. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease.
    Nakamura T; Shoji M; Harigaya Y; Watanabe M; Hosoda K; Cheung TT; Shaffer LM; Golde TE; Younkin LH; Younkin SG
    Ann Neurol; 1994 Dec; 36(6):903-11. PubMed ID: 7998778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
    Lewczuk P; Kamrowski-Kruck H; Peters O; Heuser I; Jessen F; Popp J; Bürger K; Hampel H; Frölich L; Wolf S; Prinz B; Jahn H; Luckhaus Ch; Perneczky R; Hüll M; Schröder J; Kessler H; Pantel J; Gertz HJ; Klafki HW; Kölsch H; Reulbach U; Esselmann H; Maler JM; Bibl M; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2010 Feb; 15(2):138-45. PubMed ID: 18663368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
    Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
    Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype.
    Nitsch RM; Rebeck GW; Deng M; Richardson UI; Tennis M; Schenk DB; Vigo-Pelfrey C; Lieberburg I; Wurtman RJ; Hyman BT
    Ann Neurol; 1995 Apr; 37(4):512-8. PubMed ID: 7717688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls.
    Peskind ER; Leverenz J; Farlow MR; Ito RK; Provow SA; Siegel RS; Cleveland M; Morgan CH; Pandian MR; Corbin S; Nochlin D; Schellenberg GD; Raskind MA; Wagner SL
    Alzheimer Dis Assoc Disord; 1997 Dec; 11(4):201-6. PubMed ID: 9437437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
    Zetterberg H; Andreasson U; Hansson O; Wu G; Sankaranarayanan S; Andersson ME; Buchhave P; Londos E; Umek RM; Minthon L; Simon AJ; Blennow K
    Arch Neurol; 2008 Aug; 65(8):1102-7. PubMed ID: 18695061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
    Maruyama M; Arai H; Sugita M; Tanji H; Higuchi M; Okamura N; Matsui T; Higuchi S; Matsushita S; Yoshida H; Sasaki H
    Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cerebrospinal fluid levels of beta-amyloid protein 1-42 in Alzhemier disease].
    Yi YX; Jian ZJ
    Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):171-2. PubMed ID: 12575353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
    Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
    Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Rentzos M; Paraskevas GP; Kapaki E; Nikolaou C; Zoga M; Rombos A; Tsoutsou A; Vassilopoulos D D
    J Neurol Sci; 2006 Nov; 249(2):110-4. PubMed ID: 16843497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biochemical markers for Alzheimer disease].
    Czarna JM; Waldemar G; Heegaard NH
    Ugeskr Laeger; 2006 Mar; 168(10):1010-4. PubMed ID: 16522291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
    Hampel H; Shen Y
    Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
    Galasko D
    J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An age-related correlation between levels of beta-amyloid precursor protein and beta-amyloid in human cerebrospinal fluid.
    Carroll RT; Lust MR; Kim KS; Doyle PD; Emmerling MR
    Biochem Biophys Res Commun; 1995 May; 210(2):345-9. PubMed ID: 7755609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.